38 results about "Anesthesia analgesia" patented technology

The invention discloses a multi-channel intelligent drug delivery system, which comprises: a data acquisition and transmission terminal, a TCI target control system, a wireless communication terminal,a calculation and data management terminal; The data acquisition and transmission terminal collects a scalp electrode to record an EEG signal; through the decomposition and reconstruction of the brain wave signal, the cortex and subcortical EEG can be extracted, and a two-compartment model of the cortex and subcortex is established for interactive analysis; for the pre-processed brain wave data,a waveform recognition algorithm and a wavelet analysis algorithm are applied to obtain different brain state objective theorem measurement data; A computer controlled drug-delivery technique is characterized by maintaining the drug concentration in the blood by a TCI target control system. The system can realize the analgesia and sedation monitoring during the operation, and summarizes the physiological indicator data of other monitors through a wireless data transmission technology, the concentration of an effect chamber in anesthesia is adjusted within a reasonable range, and the technicalproblem of ideal individual-specific multi-channel anesthesia analgesia and sedation is realized by the TCI technology.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a local anesthetic for an operative incision. The local anesthetic is prepared from the following traditional Chinese medicine materials in parts by weight: 5-10 parts of girald daphne bark, 5-15 parts of flos daturae, 5-10 parts of passion flower, 5-10 parts of hyoscyamus niger, 3-5 parts of decumbent corydalis tuber, 3-8 parts of shinyleaf pricklyash root, 3-5 parts of cynanchum paniculatum, 3-5 parts of centipede, 1-3 parts of caulis spatholobi, 1-3 parts of unprocessed semen strychni, 3-5 parts of asarum, 3-5 parts of arenobufagin, 3-5 parts of pepper, 3-5 parts of angelica sinensis, 3-5 parts of arisaema erubescens and 1-3 parts of flos carthami. The local anesthetic is prepared into a surgical dressing by virtue of a preparation method and used in a local anaesthesia fiber so as to be bound at an operative incision. Through the efficacies of anesthesia, analgesia, spasmolysis and convulsion check and the efficacies of drawing out poison, promoting granulation, removing blood stasis and relieving pain, the effects of rapid permeation, sedation and analgesia before an operation are achieved; the dosage of the injected local anesthetic is reduced in an assisting manner; and the local anesthetic has multiple effects of lasting anesthesia and analgesia after the operation, promoting incision healing and the like.

The invention discloses a painless microneedle and a preparation method thereof. The painless microneedle comprises a needle body and a functional layer, wherein the needle body comprises a needle handle and a needle tip; the needle handle is connected with the functional layer; the functional layer comprises a self-heating layer and a magnetic therapy layer or a traditional Chinese medicine layerarranged below the self-heating layer. The painless microneedle disclosed by the invention has the effects of slight anesthesia and analgesia, and does not cause pain after being used for a long time; the self-heating layer is provided with an isolation film which can be uncovered, and after the isolation film is uncovered, the self-heating layer makes contact with air to start heating; the magnetic therapy layer or the traditional Chinese medicine layer can dredge channels and collaterals, regulate qi and blood, resist inflammation and ease pain, and directly acts on an affected part by means of heating of the heating layer, and medicine efficacy permeation is better.

The invention provides a preparation method for a compound with a long-acting treatment effect. The compound can be used for preparing medicines having anti-depression, anesthetic or analgesic effectsor capable of improving cognitive functions, protecting the lungs, treating amyotrophic lateral sclerosis or treating complex regional pain syndrome.

The invention provides a patch for skin anesthesia, wherein the patch for skin anesthesia comprises the components in parts by weight: 2 to 15 parts of a film forming material, 0.5 to 1 part of a thickening agent, 5 to 10 parts of anesthetic, 17 to 68 parts of a transdermal absorbent, 0.1 to 0.8 part of a bacteriostatic agent and 36 to 67 parts of water. The patch for skin anesthesia is stable indosage, easy to operate, short in onset time, long in drug efficacy time and high in anesthesia analgesia depth.

The invention belongs to the field of pharmacy, and mainly relates to a non-addiction local anesthesia analgesic sustained-release drug delivery system and a method for preparing the same. The sustained-release drug delivery system comprises analgesics, solvents and sustained-release preparations. The analgesics are compositions of bupivacaine free alkali or bupivacaine salts and morphine; the solvents are one or two of ethyl alcohol, benzyl alcohol, benzyl benzoate, ethyl lactate and tetrahydrofuran polyglycol ether; the sustained-release preparations are one or two of soybean oil, ethyl oleate and castor oil. The non-addiction local anesthesia analgesic sustained-release drug delivery system and the method have the advantages that the non-addiction local anesthesia analgesic sustained-release drug delivery system is free of addiction, long in analgesic duration time and low in toxicity, obvious analgesic effects can be realized, and only few side effects can be realized; the non-addiction local anesthesia analgesic sustained-release drug delivery system is free of human tissue irritation and influence on healing of postoperative wound, and obvious local anesthesia analgesic treatment effects can be realized for the postoperative wound.

The invention relates to a pharmaceutical composition which comprises liquid oil and at least one pharmaceutically acceptable gelator. The composition is semi-solid at normal temperature, can be directly used as a medicine storage cavern at the administration part, is convenient for clinical administration, is small in irritation, and has good medication safety and tolerance. The composition is especially suitable for development of pharmaceutical preparations with anesthesia and analgesic activity, has more advantages compared with other slow-release analgesic systems, is continuous and stable in release of analgesic active ingredients, can be used for injection administration, is suitable for stable and convenient local administration, and is good in patient tolerance and few in side effects.

The invention discloses a pharmaceutical composition having abirritation and sedation, which comprises alfentanil and fospropofol disodium, wherein the weight ratio of alfentanil and fospropofol disodium is 1: (100 to 2500). The pharmaceutical composition is used in a form of a conventional medicine preparation, and a preferential medicament form is injection. By combining narcotic analgesic and narcotic sedative, better abirritation and better sedation can be realized, and times for applying medicine can be reduced, so that the anesthesia induction process is more convenient.

A multimodal anti-emetic anesthetic/analgesic formulation for pain control not limited to postoperative pain control is described herein. The opioid-free/sparing anesthetic/analgesic formulation comprises a local anesthetic, an N-methyl-D-aspartate (NMDA) receptor antagonist, and a cyclooxygenase (COX) inhibitor such as Bupivacaine Hydrochloride, Ketamine Hydrochloride, and Ketorolac Tromethamine, which is effective to significantly reduce postoperative nausea and vomiting and enhance postoperative pain relief as compared to existing prior art anesthetics/analgesics. The formulation is administered to a mammal in need of anesthesia/analgesia and can be used as a preemptive and preventative multimodal analgesic. The formulation may have a buffer to enhance its shelf life and improve pharmacokinetics. The formulation may further comprise an alpha agonist, a steroid, a Transient Receptor Potential Channel agonist or antagonist, a beta-lactam antibiotic, a protein kinase inhibitor, a competitive or non-competitive glycine or glutamate antagonist, a glutamate or glycine inhibitor, a cyclooxygenase 3 inhibitor, or combinations thereof.

The invention relates to a pharmaceutical composition. The pharmaceutical composition comprises liquid oil, a pharmaceutically acceptable gelator, a pharmaceutically acceptable stabilizer and a pharmaceutically active ingredient. The pharmaceutical composition is especially suitable for development of pharmaceutical preparations with anesthesia and analgesic activity, and has more advantages compared with other sustained-release analgesic systems, for example, release of analgesic active ingredients is continuous and stable, injection administration can be achieved, the pharmaceutical composition is suitable for stable and convenient local administration, patient tolerance is good, and side effects are few.

The invention relates to a medicament comprising a combination of a substance that blocks both the ion channel associated to NMDA receptors and MAO enzymes and a narcotic analgesic substance, preferably a fixed combination, pharmaceutical compositions thereof, and to the use thereof for the treatment of subjects suffering of various types of pain and/or for inhibiting the development of tolerance, and/or physical dependence on a narcotic analgesic substance.

The invention relates to the field of medicines, relates to application of a low-addiction HNK derivative in preparation of medicines, and in particular relates to application of the low-addiction HNKderivative in preparation of medicines for treating or preventing depression, including diseases such as complex regional pain syndrome (CRPS) and the like. The compound disclosed by the invention has a structure as shown in a formula I, and can be used for preparing medicines for preventing or treating depression, anesthesia, analgesia, cognitive function improvement, lung protection, amyotrophic lateral sclerosis or complex regional pain syndrome. Compared with the existing known HNK compounds, the compound provided by the invention has longer drug effect time, and the compound provided bythe invention basically does not generate addiction.

The invention relates to application of a long-acting low-addiction compound in preparation of medicine, in particular to application of the compound in medicine for treating or preventing depression,anesthesia and analgesia and improving cognitive function, lung protection, amyotrophic lateral sclerosis or complex regional pain syndrome. The compound is of a structure as shown in a formula I, and can treat depression, particularly bipolar depression and major depressive disorder. Compared with existing known HNK compounds, the compound has longer drug effect time, and basically does not generate addiction.